Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097029238> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2097029238 endingPage "1012" @default.
- W2097029238 startingPage "1009" @default.
- W2097029238 abstract "Tumour necrosis factor (TNF)-α is thought to play a major role in the pathophysiology of psoriasis. Good clinical responses of psoriasis to anti-TNF-α-based therapies have recently been demonstrated. We studied the effect of infliximab, a monoclonal antibody against TNF-α, on chemokine expression in pustular psoriasis. A 61-year-old man with a 2-year history of severe pustular psoriasis of von Zumbusch type who did not respond to conventional therapies responded rapidly to treatment with infliximab. The clinical response was reflected by an immediate and effective reduction of the neutrophil-attractant chemokines interleukin (IL)-8 and growth-related oncogene (Gro)-α as well as of monocyte chemoattractant protein (MCP)-1, as determined by mRNA in situ hybridization of lesional skin. No expression before or after treatment was seen for monokine induced by interferon (IFN)-γ (MIG) and IFN-inducible protein (IP)-10. Thus, in pustular psoriasis the chemokine expression pattern is dominated by neutrophil-attractant chemokines and MCP-1 while, in contrast to plaque psoriasis, IFN-γ-inducible lymphocyte-attractant chemokines such as IP-10 and MIG are not abundant. We conclude that anti-TNF-α treatment with infliximab is an effective therapy in severe pustular psoriasis which is reflected by downregulation of disease-promoting chemokines such as IL-8, Gro-α and MCP-1." @default.
- W2097029238 created "2016-06-24" @default.
- W2097029238 creator A5060451853 @default.
- W2097029238 creator A5062689869 @default.
- W2097029238 creator A5075420379 @default.
- W2097029238 creator A5076078511 @default.
- W2097029238 creator A5087860614 @default.
- W2097029238 date "2004-05-01" @default.
- W2097029238 modified "2023-09-27" @default.
- W2097029238 title "Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression" @default.
- W2097029238 cites W1978716008 @default.
- W2097029238 cites W2009680323 @default.
- W2097029238 cites W2017345251 @default.
- W2097029238 cites W2024699319 @default.
- W2097029238 cites W2026805941 @default.
- W2097029238 cites W2033275545 @default.
- W2097029238 cites W2047393615 @default.
- W2097029238 cites W2114990062 @default.
- W2097029238 cites W2171658206 @default.
- W2097029238 cites W4249483860 @default.
- W2097029238 doi "https://doi.org/10.1111/j.1365-2133.2004.05960.x" @default.
- W2097029238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15149518" @default.
- W2097029238 hasPublicationYear "2004" @default.
- W2097029238 type Work @default.
- W2097029238 sameAs 2097029238 @default.
- W2097029238 citedByCount "61" @default.
- W2097029238 countsByYear W20970292382012 @default.
- W2097029238 countsByYear W20970292382013 @default.
- W2097029238 countsByYear W20970292382014 @default.
- W2097029238 countsByYear W20970292382016 @default.
- W2097029238 countsByYear W20970292382018 @default.
- W2097029238 countsByYear W20970292382020 @default.
- W2097029238 countsByYear W20970292382021 @default.
- W2097029238 countsByYear W20970292382022 @default.
- W2097029238 countsByYear W20970292382023 @default.
- W2097029238 crossrefType "journal-article" @default.
- W2097029238 hasAuthorship W2097029238A5060451853 @default.
- W2097029238 hasAuthorship W2097029238A5062689869 @default.
- W2097029238 hasAuthorship W2097029238A5075420379 @default.
- W2097029238 hasAuthorship W2097029238A5076078511 @default.
- W2097029238 hasAuthorship W2097029238A5087860614 @default.
- W2097029238 hasConcept C13373296 @default.
- W2097029238 hasConcept C17991360 @default.
- W2097029238 hasConcept C203014093 @default.
- W2097029238 hasConcept C2776914184 @default.
- W2097029238 hasConcept C2777138892 @default.
- W2097029238 hasConcept C2779603739 @default.
- W2097029238 hasConcept C2779911711 @default.
- W2097029238 hasConcept C2780564577 @default.
- W2097029238 hasConcept C71924100 @default.
- W2097029238 hasConceptScore W2097029238C13373296 @default.
- W2097029238 hasConceptScore W2097029238C17991360 @default.
- W2097029238 hasConceptScore W2097029238C203014093 @default.
- W2097029238 hasConceptScore W2097029238C2776914184 @default.
- W2097029238 hasConceptScore W2097029238C2777138892 @default.
- W2097029238 hasConceptScore W2097029238C2779603739 @default.
- W2097029238 hasConceptScore W2097029238C2779911711 @default.
- W2097029238 hasConceptScore W2097029238C2780564577 @default.
- W2097029238 hasConceptScore W2097029238C71924100 @default.
- W2097029238 hasIssue "5" @default.
- W2097029238 hasLocation W20970292381 @default.
- W2097029238 hasLocation W20970292382 @default.
- W2097029238 hasOpenAccess W2097029238 @default.
- W2097029238 hasPrimaryLocation W20970292381 @default.
- W2097029238 hasRelatedWork W1992644783 @default.
- W2097029238 hasRelatedWork W2095027258 @default.
- W2097029238 hasRelatedWork W2118788870 @default.
- W2097029238 hasRelatedWork W2132086662 @default.
- W2097029238 hasRelatedWork W2143305956 @default.
- W2097029238 hasRelatedWork W2167191188 @default.
- W2097029238 hasRelatedWork W2360064292 @default.
- W2097029238 hasRelatedWork W250942893 @default.
- W2097029238 hasRelatedWork W2734577387 @default.
- W2097029238 hasRelatedWork W4297980453 @default.
- W2097029238 hasVolume "150" @default.
- W2097029238 isParatext "false" @default.
- W2097029238 isRetracted "false" @default.
- W2097029238 magId "2097029238" @default.
- W2097029238 workType "article" @default.